Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
Clinical trial NCT04419467 · COMPLETED
Trial details
- NCT number
- NCT04419467
- Sponsor
- CSL Behring
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-14
- Primary completion
- 2022-10-24
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.